S100A9 Induces RANKL Expression in Osteocytes Utilizing IL‐6/sIL‐6R Combination and gp130 Signaling Pathways
Eijiro Sakamoto, Tetsuya Yoshimoto, Rie Kido, Mikihito Kajiya, Hiromichi Yumoto · 2026
Read S100A9 Induces RANKL Expression in Osteocytes Utilizing IL‐6/sIL‐6R Combination and gp130 Signaling Pathways by Eijiro Sakamoto, Tetsuya Yoshimoto, Rie Kido, Mikihito Kajiya, Hiromichi Yumoto (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13662504.txt.
Description
Five researchers in Japan trace how an inflammatory protein drives bone loss signaling in a 2026 paper. Calprotectin, built from S100A8 and S100A9, runs high in diseases with inflammatory bone loss. Earlier work showed S100A9 raises RANKL, the signal that activates bone eating cells, in bone forming osteocytes.
Here S100A9 widened resorption areas and raised bone eating cell counts in mouse skull bone. Osteocytes raised both RANKL and interleukin 6 output. Immune cells shed the soluble receptor that lets interleukin 6 signal through gp130, switching on JAK1 and STAT3 in osteocytes. Blocking the cytokine or gp130 cut the effects, and a gp130 blocker curbed bone loss in live animals. The chain nominates gp130 as a drug target.
Catalog record
| CREATOR | Eijiro Sakamoto, Tetsuya Yoshimoto, Rie Kido, Mikihito Kajiya, Hiromichi Yumoto |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |